CompLEEment-1: Updated Results From the Phase IIIb Study of Ribociclib Plus Letrozole in HR+, HER2- Advanced Breast Cancer

May 29-31, 2020; Online at meetings.asco.org/am
Ribociclib plus letrozole appears safe and effective as first-line endocrine therapy in an expanded patient population with HR+, HER2- advanced breast cancer regardless of menopausal status.
Format: Microsoft PowerPoint (.ppt)
File Size: 209 KB
Released: June 1, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
GlaxoSmithKline
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation

Related Content

Expert review and discussion of key data from SABCS 2020 in HER2-positive and hormone receptor–positive/HER2-negative disease, and metastatic triple-negative breast cancer from Clinical Care Options (CCO)

Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: February 19, 2021 Expired: February 18, 2022

Download this short summary slideset oncurrent treatment for patients with HER2-positive breast cancer, from NCCN and Clinical Care Options (CCO).

Jame Abraham, MD, FACP Hope S. Rugo, MD Sara Tolaney, MD, MPH Released: February 9, 2021

Download these expert-selected slides on treating patients with HER2-positive metastatic breast cancer, from NCCN and Clinical Care Options (CCO).

Hope S. Rugo, MD Released: February 3, 2021

Download these expert-selected slides on treatment for patients with HER2-positive early breast cancer, from NCCN and Clinical Care Options (CCO).

Jame Abraham, MD, FACP Released: February 2, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue